Overview
Neurogenix Therapeutics develops small-molecule neurotrophin mimetics targeting TrkB receptors to treat treatment-resistant depression and cognitive decline.
More in Neuropharmaceuticals
Latest industry news
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Tether Evo Takes On One of BCI's Hardest Engineering Problems
2026-09-19 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
Basel, Switzerland
Funding
$28M Series B
Website
neurogenixtherapeutics.comListed
2026-06-29
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →